| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| H0018 |
Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem |
7,969 |
478 |
$1.34M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,146 |
8,518 |
$578K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
7,491 |
2,951 |
$321K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,842 |
3,351 |
$269K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,145 |
5,154 |
$245K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,717 |
1,932 |
$223K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
546 |
428 |
$190K |
| 80053 |
Comprehensive metabolic panel |
7,667 |
5,974 |
$174K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,125 |
2,586 |
$99K |
| 87631 |
|
815 |
679 |
$84K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,200 |
1,203 |
$83K |
| 97597 |
|
3,809 |
1,909 |
$81K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,041 |
1,671 |
$78K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,265 |
1,702 |
$63K |
| 80306 |
|
1,293 |
1,087 |
$58K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,232 |
7,575 |
$52K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,385 |
1,123 |
$52K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,105 |
912 |
$50K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
814 |
719 |
$47K |
| 82948 |
|
3,735 |
1,452 |
$33K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,153 |
694 |
$30K |
| 81025 |
|
1,936 |
1,641 |
$28K |
| 84484 |
|
3,261 |
2,177 |
$24K |
| 81000 |
|
3,551 |
3,009 |
$16K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,625 |
1,366 |
$15K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
150 |
143 |
$15K |
| 81002 |
|
2,186 |
1,866 |
$15K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
391 |
357 |
$14K |
| 29580 |
|
506 |
103 |
$14K |
| 83605 |
|
1,605 |
1,204 |
$12K |
| 84443 |
Thyroid stimulating hormone (TSH) |
709 |
644 |
$11K |
| 83690 |
|
2,251 |
1,870 |
$11K |
| 90834 |
Psychotherapy, 45 minutes with patient |
248 |
145 |
$10K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
192 |
165 |
$10K |
| 86140 |
|
2,163 |
1,485 |
$9K |
| 11045 |
|
178 |
79 |
$9K |
| 87077 |
|
741 |
586 |
$8K |
| 83735 |
|
2,076 |
1,628 |
$8K |
| 87088 |
|
458 |
410 |
$7K |
| G0378 |
Hospital observation service, per hour |
484 |
262 |
$6K |
| 87040 |
|
1,307 |
587 |
$6K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
108 |
59 |
$6K |
| 85610 |
|
2,021 |
1,658 |
$5K |
| 87186 |
|
977 |
773 |
$4K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,579 |
3,580 |
$4K |
| 83880 |
|
358 |
286 |
$4K |
| 87430 |
|
94 |
85 |
$3K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,618 |
1,012 |
$3K |
| 85730 |
|
1,063 |
933 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
1,276 |
1,117 |
$3K |
| 85378 |
|
597 |
513 |
$3K |
| 87070 |
|
178 |
152 |
$3K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
41 |
39 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,210 |
2,618 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
2,678 |
2,184 |
$2K |
| 87205 |
|
467 |
374 |
$1K |
| 74018 |
|
89 |
71 |
$1K |
| 84145 |
|
51 |
42 |
$922.12 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,739 |
2,152 |
$886.04 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
29 |
27 |
$768.67 |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
14 |
13 |
$715.04 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,809 |
1,762 |
$593.70 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
35 |
25 |
$550.79 |
| 84703 |
|
90 |
84 |
$536.38 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
127 |
94 |
$495.05 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
15 |
12 |
$463.41 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
15 |
12 |
$463.41 |
| 80076 |
|
77 |
71 |
$395.63 |
| 82550 |
|
91 |
71 |
$339.71 |
| 87807 |
|
15 |
14 |
$235.42 |
| 87075 |
|
31 |
26 |
$185.34 |
| 82150 |
|
35 |
30 |
$158.89 |
| 73610 |
|
13 |
13 |
$100.78 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,358 |
3,849 |
$78.27 |
| 86901 |
|
27 |
25 |
$68.81 |
| 86900 |
|
27 |
25 |
$68.81 |
| 80050 |
General health panel |
164 |
144 |
$41.03 |
| 86850 |
|
13 |
12 |
$38.42 |
| 85652 |
|
16 |
15 |
$17.32 |
| 36415 |
Collection of venous blood by venipuncture |
3,993 |
2,642 |
$12.50 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,028 |
2,317 |
$8.82 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,651 |
2,012 |
$4.60 |
| J3490 |
Unclassified drugs |
2,584 |
1,088 |
$3.30 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,537 |
1,704 |
$2.42 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
176 |
117 |
$0.35 |
| J2704 |
Injection, propofol, 10 mg |
922 |
461 |
$0.18 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
783 |
672 |
$0.16 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,710 |
1,430 |
$0.10 |
| A9270 |
Non-covered item or service |
3,095 |
1,679 |
$0.08 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,427 |
1,118 |
$0.03 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
850 |
707 |
$0.03 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
75 |
66 |
$0.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
178 |
116 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
96 |
83 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
45 |
25 |
$0.00 |
| 96376 |
|
184 |
124 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
98 |
41 |
$0.00 |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
18 |
13 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
69 |
60 |
$0.00 |
| 94760 |
|
21 |
12 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
28 |
24 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
14 |
12 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
13 |
12 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
18 |
13 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
174 |
145 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
827 |
553 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
22 |
18 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
43 |
15 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
80 |
66 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
15 |
12 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
65 |
54 |
$0.00 |
| 73630 |
|
41 |
39 |
$0.00 |